Fresenius

Group Figures

Alternative Performance Measures Interactive Tool

Strategy & Outlook

Goals and Strategy Financial Performance Indicators Group Structure Outlook

Share

Key Data Share Price Dividends Total Return Calculator Analysts & Consensus Shareholder Structure Capitalization ADR

Credit Relations

Financing Strategy & Targets Financing Mix Maturities Bonds & Convertible Bonds Commercial Paper Program Rating Key Credit Data

Our Responsibility

Our Material Sustainability Topics

Access to Healthcare

Patient and Product Safety

Employees

Diversity and Equal Opportunities

Human Rights

Digital Transformation and Innovation

Environment

ESG Rating Overview

Sustainable Development Goals

At Fresenius, we are at the heart of healthcare. For all our activities, our patients take center stage. We focus on world-class therapies, which we continuously improve to keep pace with the major trends in healthcare. Our therapy focus is reflected in three platforms: 

(Bio)Pharma

Biosimilars

IV Generics and Fluids

Clinical Nutrition

MedTech

Infusion and Nutrition Systems

Transfusion Medicine and Cell Therapies

Care Provision

Inpatient and Outpatient Treatments

Occupational Healthcare and Prevention

Reproductive Medicine 

 

Furthermore, our Investment Companies Fresenius Medical Care and Fresenius Vamed expand our offering to:

Dialysis

Apheresis

Project Business and Services

Rehabilitation, Care and Health Tourism

An open dialog with our shareholders and the financial community is important to us. The Fresenius Investor Relations team will be happy to answer all your questions and inquiries.  

 
Fresenius SE & Co. KGaA
Investor Relations
Else-Kröner-Str. 1
D-61352 Bad Homburg
Germany

T: +49 (0) 6172 608-2485
F: +49 (0) 6172 608-2488
ir-fre@fresenius.com

 
Postal address:
Fresenius SE & Co. KGaA
Investor Relations
D-61346 Bad Homburg v.d.H.

How to get to here (PDF, 2.19 MB) Route planner

Markus Georgi
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com

Karen Janek
Assistant Investor Relations
T: +49 (0) 6172 608-2487
karen.janek@fresenius.com

Silke Zimmermann
Assistentin Investor Relations
T: +49 (0) 6172 608-2464
silke.zimmermann@fresenius.com

Florian Feick
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com

Stefanie Drees
Director Investor Relations
T: +49 (0) 6172 608-5211
stefanie.drees@fresenius.com

Michael Otto
Director Investor Relations
T: +49 (0) 6172 608-2419
michael.otto@fresenius.com

Elisabeth Truckenbrodt
Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com

Felix Klein
Senior Manager Investor Relations
T: +49 (0) 6172 608-96484
felix.klein@fresenius.com

Mara Sinsel
Senior Manager Investor Relations
T: +49 (0) 6172 608-96538
mara.sinsel@fresenius.com

Annette Hainz
Manager Investor Relations
T: +49 (0) 6172 608-2604
annette.hainz@fresenius.com

Elisabeth Jung
Manager Investor Relations
T: +49 (0) 6172 608-2419
elisabeth.jung@fresenius.com

The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).

 

THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.

 

To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.

 

By clicking on the "Accept" button below, you will be deemed to have made this confirmation

 

Bonds

Issuer Volume in millionCouponMaturity

Fresenius SE & Co. KGaA

 €500 1.875% 2025

Fresenius SE & Co. KGaA

 €750 1.875% 2025

Fresenius SE & Co. KGaA

 €500 0.375% 2026

Fresenius SE & Co. KGaA

 €500 4.25% 2026

Fresenius SE & Co. KGaA

 €750 1.625% 2027

Fresenius SE & Co. KGaA

 €750 0.75% 2028

Fresenius SE & Co. KGaA

 CHF275 2.96% 2028

Fresenius SE & Co. KGaA

 €500 2.875% 2029

Fresenius SE & Co. KGaA

 €500 5.00% 2029

Fresenius SE & Co. KGaA

 €550 2.875% 2030

Fresenius SE & Co. KGaA

 €500 5.125% 2030

Fresenius SE & Co. KGaA

 €500 1.125% 2033

Fresenius Finance Ireland plc.

 €500 0.00% 2025

Fresenius Finance Ireland plc.

 €700 2.125% 2027

Fresenius Finance Ireland plc.

 €500 0.50% 2028

Fresenius Finance Ireland plc.

 €500 0.875% 2031

Fresenius Finance Ireland plc.

 €500 3.00% 2032

New information

All | None
Download

Library

General Credit Presentation (PDF, 2.02 MB)
Subscribe to